About 33 results found for searched term "Penetratin" (0.086 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M53624 | Penetratin-Arg | Antibiotic |
| Penetratin-Arg is an antimicrobial and is used for drug delivery vehicle. | ||
| M53874 | Cys-Penetratin | Others |
| Cys-Penetratin is a cell-penetrating peptide (CPP) with sequence of CRQIKIWFQNRRMKWKK. | ||
| M54006 | Penetratin | Others |
| Penetratin is a peptide derived from the amphiphilic Drosophila Antennapedia homeodomain. | ||
| M4926 | Fosfomycin calcium | Antibiotic |
| Phosphomycin calcium salt; MK-0955 calcium | ||
| Fosfomycin (MK-0955) calcium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin calcium shows both in vivo and in vitro activity against a wide range of bacteria. | ||
| M5729 | Latanoprost | Prostaglandin Receptor |
| Xalatan, PhXA41, PHXA-41 | ||
| Latanoprost is a prostaglandin F2α analog as well as a prostaglandin-like selective FP receptor agonist with lipophilic and corneal penetrating properties. In addition, Latanoprost also increases ocular fluid outflow, thereby reducing intraocular pressure, and may be used in studies related to glaucoma. | ||
| M6311 | GO-203 | Others |
| GO-203 is a D-amino acid cell-penetrating peptide inhibitor of MUC1-C dimerization and thereby its oncogenic function. | ||
| M8258 | KYP-2047 | Apoptosis |
| KYP2047 | ||
| KYP-2047 is a potent and BBB-penetrating prolyl-oligopeptidase (POP) inhibitor, with an Ki value of 0.023 nM. KYP-2047 reduces glioblastoma proliferation through angiogenesis and apoptosis modulation. | ||
| M10158 | AZ32 | ATM/ATR |
| AZ-32 | ||
| AZ32 is an orally bioavailable and blood-brain barrier-(BBB)penetrating inhibitor of ATM with IC50 of <6.2 nM and 0.31 μM for ATM enzyme in cell. | ||
| M10207 | HIV-1 TAT Peptide TFA | HIV Protease |
| HIV-1 tat Protein (47-57) | ||
| TAT TFA is a cell-penetrating peptide which derived from the transactivator of transcription (TAT) of human immunodeficiency virus (HIV-1). | ||
| M13392 | GeA-69 | PARP |
| GeA-69 is a cell-penetrating selective allosteric inhibitor targeting Macrodomain 2 (MD2) with a Kd of 2.1 µM. | ||
| M13755 | iRGD peptide | Integrin |
| c(CRGDKGPDC) | ||
| iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. | ||
| M13899 | SR59230A hydrochloride | Adrenergic Receptor |
| SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively. | ||
| M14096 | TLR1 | Others |
| TLR1 (compound 4a) is a low molecular weight, cell-penetrating Toll/IL-1 receptor/resistance (TIR) domain/BB-Loop mimic. TLR1 inhibits IL-1 receptor-mediated responses. | ||
| M14808 | (Arg)9 TFA | Peptides |
| Nona-L-arginine TFA; Peptide R9 TFA | ||
| (Arg)9 TFA (Nona-L-arginine TFA), a cell-penetrating peptide, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model. | ||
| M14823 | Rabies Virus Glycoprotein TFA | Peptides |
| Rabies Virus Glycoprotein (TFA) is a 29-amino-acid cell penetrating peptide derived from a rabies virus glycoprotein that can cross the blood-brain barrier (BBB) and enter brain cells. | ||
| M14826 | SPACE peptide | Peptides |
| SPACE peptide is a skin penetrating peptide (SPPs). SPACE peptide can enhance topical delivery of a macromolecule, hyaluronic acid. | ||
| M19937 | Fosfomycin Disodium | Antibiotic |
| Phosphonemycin Disodium; MK-0955 sodium | ||
| Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria. | ||
| M20005 | TAT-DEF-Elk-1 TFA | Peptides |
| TDE TFA | ||
| TAT-DEF-Elk-1 TFA (TDE TFA) is a cell-penetrating peptide inhibitor of Elk-1 that achieves inhibition by mimicking and specifically interfering with the DEF structural domain of Elk-1. Sequence: Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Pro-Ser-Pro-Ala-Lys-Leu-Ser-Phe-Gln-Phe-Pro-Ser-Ser-Gly-Ser-Ala-Gln-Val-His-Ile. | ||
| M20013 | MRTX0902 | Ras |
| MRTX0902 is an oral brain penetrating SOS1:KRAS protein-protein interaction inhibitor with an IC50 of 46 nM. | ||
| M20404 | Tryptamine | TAAR |
| Tryptamine is a monoamine alkaloid and may play a role as a neuromodulator or neurotransmitter. It is an agonist of hTAAR1. It acts as a non-selective serotonin receptor agonist and serotonin-norepinephrine-dopamine releasing agent (SNDRA). Tryptamine is a selective, blood-brain-penetrating 5-HT4 receptor agonist (EC50=1-3 mM) and an endogenous ligand of the aryl hydrocarbon receptor (AHR) (Kd=10-50 nM). Tryptamine promotes intestinal anion secretion and fluid transport by activating G protein-coupled receptors (GPCRs). | ||
| M21077 | BMS-986176 | Others |
| LX-9211; AAK1-IN-1 | ||
| BMS-986176/LX-9211 is an orally administered, CNS-penetrating AAK1 kinase inhibitor with an IC50 of 2 nM that is being developed for use in neuropathic pain studies. | ||
| M21082 | ABBV-318 | Sodium Channel |
| ABBV-318 is a CNS-penetrating oral inhibitor of Nav1.7/Nav1.8 with IC50 values of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8, respectively, and is being developed for pain studies. | ||
| M21093 | NVP-CLR457 | PI3K |
| NVP-CLR457 is an orally administered, non-CNS-penetrating, pan-IA-like phosphoinositide 3-kinase (PI3K) inhibitor.NVP-CLR457 shows a significant dose-dependent PK / PD / efficacy relationship.NVP-CLR457 has antitumor activity. | ||
| M21358 | Certepetide | Integrin |
| CEND-1; iRGD; LSTA1 | ||
| Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating peptide whose RGD motif interacts with alphav-integrins and activates neurofibrillary protein 1 (NRP-1) to transform the solid tumor microenvironment into a temporary drug pipeline. Sequence Shortening: Ac-CRGDKGPDC-NH2 (Disulfide bridge: Cys1-Cys9). | ||
| M21516 | PZ-128 | PAR |
| P1pal-7 | ||
| PZ-128 (P1pal-7), a cell-penetrating peptide, is a first-in-class, specific and reversible protease activating receptor 1 (PAR1) antagonist. It has anti-platelet, anti-metastasis, anti-angiogenesis and anticancer effects. | ||
| M21576 | PTC258 | Others |
| PTC258 is an oral, brain-penetrating splicing modulator targeting ELP1. | ||
| M21693 | ReACp53 | p53 |
| HRRRRRRRRRRPILTRITLE-OH | ||
| ReACp53 is a cell-penetrating peptide inhibitor of p53 aggregation, inhibits p53 amyloid formation, rescues p53 function in cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC). | ||
| M21786 | ACT-709478 | Calcium Channel |
| NBI-827104 | ||
| ACT-709478 is a selective, orally active and brain-penetrating T-type calcium channel blocker (Cav3.1, Cav 3.2, Cav 3.3). | ||
| M24820 | Valanafusp alfa | Insulin Receptor |
| AGT-181; HIRMAb-IDUA | ||
| Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) . | ||
| M24949 | Clervonafusp alfa | Others |
| VAL-1221 | ||
| Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research. | ||
| M25537 | TAT-DEF-Elk-1 acetate | Peptides |
| TDE acetate | ||
| TAT-DEF-Elk-1 acetate (TDE acetate) is a cell-penetrating peptide inhibitor of Elk-1 that achieves inhibition by mimicking and specifically interfering with the DEF structural domain of Elk-1. | ||
| M27798 | SNT-207858 | Melanocortin Receptor |
| SNT207858 is a selective, blood brain barrier penetrating, potent and orally active melanocortin-4 (MC-4) receptor antagonist. SNT207858 has an IC50 of 22 nM (binding) and 11 nM (function) on the MC-4 receptor. | ||
| M27800 | SNT-207858 free base | Melanocortin Receptor |
| SNT207858 free base is a selective, blood brain barrier penetrating, potent and orally active melanocortin-4 (MC-4) receptor antagonist. SNT207858 free base has an IC50 of 22 nM (binding) and 11 nM (function) on the MC-4 receptor. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
